Cargando…

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use

OBJECTIVES: Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide, though with limited success. This analysis evaluated the efficacy of eluxadoline in patients previously treated with loperamide in two phase 3 studies. METHODS: Adults with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lacy, Brian E, Chey, William D, Cash, Brooks D, Lembo, Anthony J, Dove, Leonard S, Covington, Paul S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Functional GI Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465428/ https://www.ncbi.nlm.nih.gov/pubmed/28417992 http://dx.doi.org/10.1038/ajg.2017.72

Ejemplares similares

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation
por: Chey, William D, et al.
Publicado: (2011)

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials
por: Lacy, Brian E., et al.
Publicado: (2019)

Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus
por: Rezaie, Ali, et al.
Publicado: (2017)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome
por: Marquis, P, et al.
Publicado: (2014)

Effects of treatment with eluxadoline on abdominal pain in patients with IBS‐D: Additional post hoc analyses of Phase 3 trials
por: Lembo, Anthony J., et al.
Publicado: (2020)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Prucalopride in Men With Chronic Constipation
por: Yiannakou, Yan, et al.
Publicado: (2015)

A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation
por: Miner Jr, Philip B, et al.
Publicado: (2017)

Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea
por: Pattni, Sanjeev S, et al.
Publicado: (2012)

Prucalopride Improves Bowel Function and Colonic Transit Time in Patients With Chronic Constipation: An Integrated Analysis
por: Emmanuel, Anton, et al.
Publicado: (2014)

The Epidemiology of Irritable Bowel Syndrome in the US Military: Findings from the Millennium Cohort Study
por: Riddle, Mark S, et al.
Publicado: (2016)

Association Between the Location of Diverticular Disease and the Irritable Bowel Syndrome: A Multicenter Study in Japan
por: Yamada, Eiji, et al.
Publicado: (2014)

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
por: Jamal, M Mazen, et al.
Publicado: (2015)

The Effect of High-Fat Diet-Induced Pathophysiological Changes in the Gut on Obesity: What Should be the Ideal Treatment?
por: Y Lee, Chooi
Publicado: (2013)

Distinct Abnormalities of Small Bowel and Regional Colonic Volumes in Subtypes of Irritable Bowel Syndrome Revealed by MRI
por: Lam, Ching, et al.
Publicado: (2017)

Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome
por: Sayuk, Gregory S, et al.
Publicado: (2017)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study
por: Brenner, Darren M., et al.
Publicado: (2019)

Evaluation of Eluxadoline Effect on Cardiac Repolarization
por: Bonifacio, Laura, et al.
Publicado: (2018)

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
por: Chey, W. D., et al.
Publicado: (2017)

Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change
por: Cash, Brooks D., et al.
Publicado: (2021)

Functional bowel symptoms, fibromyalgia and fatigue: A food-induced triad?
por: Berstad, Arnold, et al.
Publicado: (2012)

Diagnostic pitfalls in functional neurological disorders
por: Pimentel, Lucio Huebra, et al.
Publicado: (2022)

Subclonal diversity arises early even in small colorectal tumours and contributes to differential growth fates
por: Sievers, Chelsie K, et al.
Publicado: (2017)

Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide
por: Brenner, Darren M, et al.
Publicado: (2021)

Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis
por: Appleby, Richard N, et al.
Publicado: (2017)

Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers
por: Fujita, Wakako, et al.
Publicado: (2014)

Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt
por: Nakae, Hirohiko, et al.
Publicado: (2016)

Alteration in the gastric microbiota and its restoration by probiotics in patients with functional dyspepsia
por: Igarashi, Muneki, et al.
Publicado: (2017)

‘What puts the ‘Hic’ into Hiccups?’
por: Seifi, Ali, et al.
Publicado: (2022)

Practical multidisciplinary framework for the assessment and management of patients with unexplained chronic aerodigestive symptoms
por: Quigley, Nathan, et al.
Publicado: (2023)

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
por: Levy-Cooperman, N., et al.
Publicado: (2016)

Endoscopic stent insertion for anastomotic leakage following oesophagectomy
por: Schweigert, M, et al.
Publicado: (2013)

Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures
por: Arechederra, Maria, et al.
Publicado: (2022)

Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline
por: Davenport, J Michael, et al.
Publicado: (2015)

Constipation-related direct medical costs in 16 887 patients newly diagnosed with chronic constipation
por: Dik, Vincent K., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_h3utrg53vn2osg1tqh57rvbv6r